Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 36, Pages 4073-4126
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-11-02
DOI
10.1200/jco.21.01440
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
- (2021) A. Gault et al. BRITISH JOURNAL OF DERMATOLOGY
- Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy
- (2021) Monika F. Keiser et al. Clinical Lung Cancer
- Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society
- (2021) Takeshi Johkoh et al. RADIOLOGY
- Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
- (2021) Fangwen Zou et al. Journal for ImmunoTherapy of Cancer
- Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
- (2021) Tamara A Sussman et al. Journal for ImmunoTherapy of Cancer
- Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
- (2021) Aanika Balaji et al. Journal for ImmunoTherapy of Cancer
- Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
- (2021) Anusha S. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
- (2021) Jason Beattie et al. Journal for ImmunoTherapy of Cancer
- Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum
- (2020) Divyanshu Dubey et al. ANNALS OF NEUROLOGY
- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-related adverse events and efficacy outcomes in patients treated with immunotherapy: A systematic review and meta-analysis.
- (2020) Eric Druyts et al. JOURNAL OF CLINICAL ONCOLOGY
- It Is Time to Talk About Fertility and Immunotherapy
- (2020) Narjust Duma et al. ONCOLOGIST
- Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
- (2020) Xiaowei Liu et al. Thoracic Cancer
- Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
- (2020) Kari Ala‐Leppilampi et al. Cancer Medicine
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
- (2020) Sarah Abou Alaiwi et al. Journal for ImmunoTherapy of Cancer
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
- (2020) Marie Kostine et al. ANNALS OF THE RHEUMATIC DISEASES
- Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.
- (2020) Jessica Cecile Hassel et al. JOURNAL OF CLINICAL ONCOLOGY
- Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.
- (2020) Qian Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous adverse reactions to anti-PD-1 treatment – a systematic review
- (2020) Anne Birgitte Simonsen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events
- (2020) Amaris N. Geisler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
- (2020) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy
- (2020) Kaustav P Shah et al. Cancer Immunology Research
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
- (2020) Maha Mamoor et al. Journal for ImmunoTherapy of Cancer
- COVID-19 and immune checkpoint inhibitors: initial considerations
- (2020) Ryan J Sullivan et al. Journal for ImmunoTherapy of Cancer
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Cutaneous immune-related adverse events to checkpoint inhibitors
- (2020) Neeta Malviya et al. CLINICS IN DERMATOLOGY
- Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
- (2020) Anastasiya Muntyanu et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
- (2020) X. Long Zheng et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic
- (2020) Hsu-Liang Chang et al. LUNG CANCER
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
- (2020) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Chronic immune checkpoint inhibitor pneumonitis
- (2020) Jarushka Naidoo et al. Journal for ImmunoTherapy of Cancer
- Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
- (2020) Stefania Cuzzubbo et al. Journal for ImmunoTherapy of Cancer
- Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
- (2020) Florian Moik et al. BLOOD
- Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
- (2020) Ying Jing et al. Nature Communications
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
- (2020) Syed Hussaini et al. CANCER TREATMENT REVIEWS
- Abstract 15395: Immune Checkpoint Inhibitors for Cancer Are Associated With Increased Venous Thromboembolism Events
- (2020) Jingyi Gong et al. CIRCULATION
- Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors
- (2020) Jeffrey Aldrich et al. Arthritis & Rheumatology
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
- (2020) Jennifer Cautela et al. Journal for ImmunoTherapy of Cancer
- Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
- (2020) Marion Allouchery et al. Journal for ImmunoTherapy of Cancer
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
- (2020) Si-Qi Tang et al. Cancer Research and Treatment
- Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
- (2019) Abdul Rafeh Naqash et al. Journal for ImmunoTherapy of Cancer
- Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
- (2019) Hao Chi Zhang et al. Journal for ImmunoTherapy of Cancer
- Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Hematologic Complications of Immune Checkpoint Inhibitors
- (2019) Elizabeth J. Davis et al. ONCOLOGIST
- Combined immune therapy grade IV dermatitis in metastatic melanoma
- (2019) Manreet Randhawa et al. Asia-Pacific Journal of Clinical Oncology
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Post-shingles granulomatous dermatosis related to anti-programmed cell death 1
- (2019) Tarek Assi et al. Immunotherapy
- Dermal elastolysis in the setting of combination immunotherapy
- (2019) Kirsten E Dickinson et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors
- (2019) Min Xu et al. NEUROLOGIST
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
- (2019) Tenglong Tang et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
- (2019) Aine O’Reilly et al. SUPPORTIVE CARE IN CANCER
- Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
- (2019) Sang T. Kim et al. Journal for ImmunoTherapy of Cancer
- Cutaneous Adverse Reactions of Anticancer Agents
- (2019) Subuhi Kaul et al. DERMATOLOGIC CLINICS
- Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma
- (2019) Erika F. Rodriguez et al. HUMAN PATHOLOGY
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
- (2019) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
- (2019) Charles L. Shapiro et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
- (2019) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment
- (2019) Dimitri Psimaras et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
- (2019) Emanuel Raschi et al. ONCOLOGIST
- Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer
- (2019) Giulia Galli et al. TUMORI
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
- (2019) Deniz C Guven et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Radiation-Induced Lung Injury (RILI)
- (2019) Lorena Giuranno et al. Frontiers in Oncology
- The Future of Immunotherapy in the Treatment of Cancer
- (2019) Lisa A. Kottschade Seminars in Oncology Nursing
- Variations of Diagnosis and Management of Immune Checkpoint Inhibitor Pancreatic Injury (ICIPI) and Immune Checkpoint Inhibitor Pancreatitis: A Single Institution Experience
- (2019) Ravi Shah et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study
- (2019) Samy Babai et al. DRUG SAFETY
- Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
- (2019) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
- (2019) Nora Möhn et al. Journal of Clinical Medicine
- Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
- (2019) Yosuke Ando et al. INVESTIGATIONAL NEW DRUGS
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
- (2019) Federico Nichetti et al. Cancers
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Cutaneous toxicities of new treatments for melanoma
- (2018) A. Boada et al. Clinical & Translational Oncology
- Vasculitis associated with immune checkpoint inhibitors—a systematic review
- (2018) Anisha Daxini et al. CLINICAL RHEUMATOLOGY
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
- (2018) Adriana T. Lopez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
- (2018) Kei Kunimasa et al. INVESTIGATIONAL NEW DRUGS
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2018) Kutluk Oktay et al. JOURNAL OF CLINICAL ONCOLOGY
- Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
- (2018) Jeanne Carter et al. JOURNAL OF CLINICAL ONCOLOGY
- Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern
- (2018) Celestine Trinidad et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis)
- (2018) Shelby L. Kubicki et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
- (2018) Charles Kyung Min Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- (2018) Jacob Siegel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Myositis as an adverse event of immune checkpoint blockade for cancer therapy
- (2018) Mohsin Shah et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
- (2018) Taku Fujimura et al. Oncotarget
- Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases
- (2018) Marie Donaldson et al. JAMA Dermatology
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
- (2018) Leo L. Wang et al. JAMA Dermatology
- Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
- (2018) Chun-Bing Chen et al. Cancer Management and Research
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
- (2018) William L. Hwang et al. JAMA Oncology
- Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
- (2018) Fausto Petrelli et al. EUROPEAN JOURNAL OF CANCER
- Drug-induced oral lichenoid reaction during nivolumab therapy
- (2018) Y. Enomoto et al. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
- (2018) Shelly Ann Christiansen et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy
- (2018) Andrew Hwang et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- (2018) Mario Lacouture et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- (2018) C. Grávalos et al. Clinical & Translational Oncology
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Diagnosis and Management of Immune Checkpoint Inhibitor‐Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
- (2018) Kerry L. Reynolds et al. ONCOLOGIST
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment
- (2017) Laura C Cappelli et al. Immunotherapy
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
- (2017) Timothy Gilligan et al. JOURNAL OF CLINICAL ONCOLOGY
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Betty R. Ferrell et al. JOURNAL OF CLINICAL ONCOLOGY
- Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients
- (2017) Michael T. Tetzlaff et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
- (2017) Mirjana Ziemer et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
- (2017) Sophie Feng et al. Journal of Thoracic Oncology
- New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
- (2017) Juliane Behling et al. MELANOMA RESEARCH
- Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
- (2017) Richard Barnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
- (2017) Animesh Jain et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer
- (2017) Noelia Rivera et al. JAMA Dermatology
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
- (2017) Justin C. Kao et al. JAMA Neurology
- Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
- (2017) Maria E. Suarez-Almazor et al. Arthritis & Rheumatology
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- (2017) Daniel Y. Wang et al. Current Cardiology Reports
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
- (2017) D. Berman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma
- (2017) J. S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- (2017) R. A. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
- (2016) C. L. Boils et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
- (2016) T. Alhamad et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
- (2016) Leonard Calabrese et al. ANNALS OF THE RHEUMATIC DISEASES
- Pulmonary sarcoid-like granulomatosis induced by nivolumab
- (2016) H. Montaudié et al. BRITISH JOURNAL OF DERMATOLOGY
- Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study
- (2016) James Turvill et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
- (2016) François-Xavier Danlos et al. CHEST
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- (2016) Eduard Cornelis Verschuren et al. Clinical Gastroenterology and Hepatology
- Programmed cell death-1 pathway inhibitors in genitourinary malignancies
- (2016) Abhishek Tripathi et al. CURRENT OPINION IN UROLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
- (2016) Maria Fleseriu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
- (2016) Stefan R. Bornstein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- (2016) Frank B. Cortazar et al. KIDNEY INTERNATIONAL
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus
- (2016) Kyoko Inadomi et al. MEDICINE
- Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia
- (2016) Ranjit Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
- (2016) Evan J. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer
- (2016) Grainne M. O'Kane et al. ONCOLOGIST
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
- (2016) Tanya J. Williams et al. JAMA Neurology
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
- (2016) Joshua E. Reuss et al. Journal for ImmunoTherapy of Cancer
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
- (2015) Mahmoud H Mosli et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
- (2015) Michael Sandherr et al. ANNALS OF HEMATOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- How I treat refractory thrombotic thrombocytopenic purpura
- (2015) Farzana A. Sayani et al. BLOOD
- Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery
- (2015) Emily K. Wright et al. GASTROENTEROLOGY
- Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Immunotherapy
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced colitis in patients with metastatic melanoma
- (2015) Kara M. De Felice et al. MELANOMA RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation
- (2014) Julienne E. Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation
- (2014) Barbara L. Andersen et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
- (2014) Jacqueline Jonklaas et al. THYROID
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
- (2013) Igor Z. Barjaktarevic et al. CHEST
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial
- (2012) Chester V. Oddis et al. ARTHRITIS AND RHEUMATISM
- Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
- (2012) Caroline Voskens et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- More on Hemophilia A Induced by Ipilimumab
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
- (2012) Jeffrey R. Garber et al. THYROID
- Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
- (2011) Richard N Shiffman et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe interstitial pneumonitis associated with the administration of taxanes
- (2010) Shigeyuki Nagata et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Advances in the understanding of acquired haemophilia A: implications for clinical practice
- (2009) Peter W. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- Infliximab for the treatment of refractory scleritis
- (2009) P. Doctor et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
- (2009) Erika von Euw et al. Journal of Translational Medicine
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started